Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IN 10 003 formulation A · 1 trial · 1 indication
To determine the effect of IN 10 003 on Wake time After Sleep Onset (WASO) as the change from baseline for the mean of night 1 and 2 relative to placebo
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | IN 10 003 formulation A |
| 2 | ACTIVE_COMPARATOR | IN 10 003 formulation B |
| 3 | PLACEBO_COMPARATOR | Placebo capsules |
| Name | Type | Description |
|---|---|---|
| IN 10 003 formulation A | DRUG | - |
| IN 10 003 formulation B | DRUG | - |
| Placebo capsules | DRUG | - |
Inclusion Criteria: * Subjects between the ages of 18 and 65 years of age * Subjects that meet DSM IV diagnostic criteria for Insomnia * Subjects that report a time in bed NLT 6.5 and NMT 9 hours * Subjects that report on a one week sleep diary (on at least 3 of 7 nights) TST NMT 6.5 hours * Subjec...
IN 10 003 formulation A is an investigational small molecule being studied for the treatment of insomnia in subjects who have difficulty falling asleep and staying asleep. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
IN 10 003 formulation A is being developed by Indaptus Therapeutics, Inc., a company listed on the stock exchange under the ticker symbol INDP. The drug is currently in Phase 2 clinical development for insomnia.
IN 10 003 formulation A is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed for this drug.
IN 10 003 formulation A has one completed Phase 2 clinical trial, identified as NCT01196650. This trial compared IN 10 003 to placebo in subjects with insomnia suffering from difficulty falling asleep and staying asleep. The trial was conducted in Israel with 24 participants.
IN 10 003 formulation A is a specific formulation of the drug IN 10 003. The clinical trial NCT01196650 refers to the drug as IN 10 003, and the formulation A designation indicates a particular version being studied for insomnia.